DNA topoisomerase II-dependent cytotoxicity of alkylaminoanthraquinones and their N-oxides

Cancer Chemotherapy and Pharmacology

Volumn 39, Issue 5, 1997, Pages 455-461

  Smith, Paul J ^a,b   Blunt, Nicola J ^b   Desnoyers, Rodwige ^b,c   Giles, Yvonne ^d   Patterson, Laurence H ^d  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d DE MONTFORT UNIVERSITY   (United Kingdom)

Author keywords

Anthraquinone prodrugs; Bioreduction; DNA intercalation; DNA topoisomerases; Mitoxantrone

Indexed keywords

ANTHRAQUINONE DERIVATIVE; DNA TOPOISOMERASE (ATP HYDROLYSING); MITOXANTRONE; PRODRUG;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS INHIBITION; DRUG ACTIVITY; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DNA BINDING; TUMOR CELL;

ANTHRAQUINONES; ANTINEOPLASTIC AGENTS; ATAXIA TELANGIECTASIA; CELL LINE; CELL LINE, TRANSFORMED; CELL SURVIVAL; CROSS-LINKING REAGENTS; DNA; DNA REPLICATION; DNA TOPOISOMERASES, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MITOXANTRONE; OXIDES; PROTEIN BINDING; SIMIAN VIRUS 40; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR STEM CELL ASSAY;

EID: 0031040944     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050598     Document Type: Article

References (23)

1. Bownden GT, Roberts R, Alberts DS, Peng Y-M, Garcia D (1985) Comparative molecular pharmacology in leukaemic L1210 cells of the anthracene anticancer drugs mitoxantrone and bisantrene. Cancer Res 45:4915
2. Brown JM, Giaccia AJ (1994) Tumour hypoxia: the picture has changed in the 1990s. Int J Radiat Biol 65:95
3. Cress AE, Roberts RA, Bowden GT, Dalton WS (1988) Modification of keratin by the chemotherapeutic drug mitoxantrone. Biochem Pharmacol 37:3043
4. Drake FH, Hofmann GA, Bartus HF, Mattern MR, Crooke ST, Mirabelli CK (1989) Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 28:8154
5. Fox ME, Smith PJ (1990) Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumour DNA intercalators mAMSA and mitoxantrone. Cancer Res 50:5813
6. Heck MM, Hittelman WN, Earnshaw WC (1988) Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc Natl Acad Sci USA 85:1086
7. Liu LF (1989) DNA topoisomerase poisons as anti-tumour drugs. Annu Rev Biochem 58:351
8. Mckeown SR, Hejmadi MV, McIntyre IA, McAleer JJA, Patterson LH (1995) AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo. Br J Cancer 72:76
9. Overgaard J (1989) Sensitization of hypoxic tumour cells clinical experience. Int J Radiat Biol 56:801
10. 123I-iodazomycin arabinoside: preliminary report of a clinical study. Br J Cancer 65:90
11. Patterson LH (1989) Anthraquinone anticancer compounds with (disubstituted amino-N-oxide)alkylamino substituent. UK Patent GB 2 237 283, UK Patent Bureau, London
12. Patterson LH (1993) Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent. Cancer Metastasis Rev 12:119
13. Patterson LH, Maine JE, Cairns DC, Craven MR, Bennett N, Fisher GR, Ruparelia K, Giles Y (1992) N-oxides of DNA affinic agents as bioreductivety activated prodrugs. Proc Am Soc Cancer Res 33:2571
14. Patterson LH, Craven MR, Fisher GR (1994) Aliphatic amine N-oxides of DNA binding agents as bioreductive drugs. Oncol Res 6:533
15. Roberts RA, Cress AE, Dalton WS (1989) Persistent intracellular binding of mitoxantrone in a human colon carcinoma cell line. Biochem Pharmacol 38:4283
16. Rowe TC, Chen GL, Hsiang Y-H, Liu LF (1986) DNA damage by antitumour acridines mediated by mammalian DNA topoisomerase II. Cancer Res 46:2021
17. Sahai BM, Kaplan JG (1986) A quantitative decatenation assay for type II topoisomerases. Anal Biochem 156:134
18. Shenkenberg TD, Von Hoff DD (1986) Mitoxantrone: a new anti-cancer drug with significant clinical activity. Ann Intern Med 105:67
19. Smith PJ, Makinson TA (1989) Cellular consequences of overproduction of DNA topoisomerase II in an ataxia-telangiectasia cell line. Cancer Res 49:1118
20. Smith PJ, Morgan SA, Fox ME, Watson JV (1990) Mitoxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multi-drug resistant small cell lung cancer cells. Biochem Pharmacol 40:2069
21. Smith PJ, Sykes HR, Fox ME, Furlong IJ (1992) Subcellular distribution of the anticancer drug mitoxantrone in human and drug-resistant murine cells analyzed by flow cytometry and confocal microscopy and its relationship to the induction of DNA damage. Cancer Res 52:1
22. Wang JC (1987) Recent studies of DNA topoisomerases. Biochim Biophys Acta 909: 1
23. Watson JV (1978) A linear transform of the multi-target survival curve. Br J Radiol 51:534